UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

______________________

 

 

Date of Report (Date of earliest event reported): October 29, 2012

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

 

Nevada 0-21617 23-2577138
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
     

621 N. Shady Retreat Road

Doylestown, PA

18901 
(Address of principal executive offices) (Zip Code)

 

Company’s telephone number, including area code: (215) 345-0919

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01 Other Events.

 

ProPhase Labs, Inc. issued a press release on October 29, 2012 relating to the unsolicited proposal received from Matrixx Initiatives, Inc., which is attached as Exhibit 99.1.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

No. Description
   
99.1 Press Release issued October 29, 2012

 

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  ProPhase Labs, Inc.
   
   
  By:  /s/ Robert V. Cuddihy, Jr.
    Robert V. Cuddihy, Jr.
Chief Operating Officer and Chief Financial Officer

 

Date: November 1, 2012